

**This communication should be viewed by:**

Primary Care Providers  
Behavioral Health Providers  
Clinical staff

## GLP-1 Receptor Agonist Coverage Update

MVP Health Care® (MVP) is committed to providing excellent customer service and keeping you informed. We want to make sure you are aware of MVP Formulary changes and how they may affect your patients, our Members.

Recently, the prescription drugs Mounjaro and Ozempic, both used to treat type 2 diabetes, have had extensive media coverage as “weight loss” medications. Both drugs are part of a class of medications called GLP-1 Receptor Agonists (GLP-1 RA). This class includes other medications to treat type 2 diabetes such as Victoza, Rybelsus, and Byetta.

Today, there are only two GLP-1 RA medications, Saxenda and Wegovy, that are specifically approved by the Food and Drug Administration (FDA) for the treatment of obesity and weight management. All other medications in the class (including Mounjaro and Ozempic) are not FDA approved for weight management and are considered “off-label” uses.

Off-label use is not a covered MVP benefit if the usage is not supported by a drug compendium such as the NCCN Drugs and Biologics Compendium or Micromedex DrugDex®. Additional information can be found in several MVP Policies: *Experimental or Investigational Procedures, Behavioral Health Services, Drugs and Treatments, Off-Label use of FDA Approved Drugs, and Clinical Trials.*

The increase in off-label use has led to shortages impacting Members living with type 2 diabetes who are dependent on these important medications for adequate blood sugar control. We are committed to overcoming access barriers and ensuring that Members receive their medications. In response, MVP is in the process of implementing utilization management starting November 1, 2023 for these medications to ensure appropriate usage based on FDA approved labeling. The GLP-1 Receptor Agonist Prospective policy is currently available for viewing on the MVP Provider website.

We understand this change may inconvenience Members using these medications for weight management. MVP is committed to helping Members continue their wellness journey. The following lists other options that are covered under your patients’ MVP health plan:

- Review other FDA approved weight loss medications with your patients such as phentermine, Contrave, Wegovy and Saxenda. MVP currently covers these medications on the MVP Commercial Formulary. To review the Commercial Formulary, visit [mvphealthcare.com/prescriptions](https://mvphealthcare.com/prescriptions), select *State, Year, and Plan*, and then select *View PDF*
- Nutrition counseling is a covered medical benefit. Members and/or Providers can visit [mvphealthcare.com/FindaDoctor](https://mvphealthcare.com/FindaDoctor) to search for a nutritionist or dietitian
- Find additional nutrition and weight loss resources available on our website, visit [mvphealthcare.com/HealthandWellness](https://mvphealthcare.com/HealthandWellness) and select *Weight Loss Resources*

For more information about MVP’s prescription drug coverage, or for a complete list of Formulary alternatives, visit [mvphealthcare.com/providers/pharmacy](https://mvphealthcare.com/providers/pharmacy). If you have any questions, please call the MVP Customer Care Center for Provider Services at **1-800-684-9286**, Monday through Friday 8:30 am–5 pm.

### It’s Time to Recertify Your Patients!\*

The Families First Coronavirus Response Act has expired. To learn how MVP can help your patients continue their coverage, visit [mvphealthcare.com/recertification](https://mvphealthcare.com/recertification).

\*Applies to Members enrolled in Medicaid, Child Health Plus (CHP), Health and Recovery Plan (HARP), and the Essential Plan (EP).

To view all communications, visit [mvphealthcare.com/FastFax](https://mvphealthcare.com/FastFax).

**Questions?** Contact your MVP Professional Relations Representative or call the MVP Customer Care Center for Provider Services at **1-800-684-9286**.

